News | November 13, 2024
Hikal Q2 FY25 revenue stood at Rs. 453 Cr
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
Infant Mortality Rate in Bihar came down from 42 to 27 in 2020, and in Jharkhand, from 34 to 25 in 2020
Giri is currently the President (India Business & Emerging Markets) of Amneal Pharmaceuticals
India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI
Subscribe To Our Newsletter & Stay Updated
